Xenon Pharmaceuticals Inc. announced at the AGM held on June 03, 2021, the shareholder elected Elizabeth Garofalo was elected to our Board of Directors at the Annual Meeting. Dr. Garofalo brings an immense amount of experience in the pharmaceutical industry with a particular focus on neurology development. Since 2016, Dr. Elizabeth Garofalo has served as the principal for EAG Pharma Consulting LLC. Previously, she served in numerous leadership roles including as Senior Vice President and Global Head of Clinical Development for Novartis and as a member of its Global Development Leadership Team; Chair of the Novartis Portfolio Stewardship Board; Co-Head of the Novartis Neuroscience Franchise; Head of the Neuroscience Therapy Area at Astellas; Ann Arbor Site Head of Worldwide Regulatory Affairs at Pfizer; and Ann Arbor Site Head of Neuroscience at Pfizer. Since September 2020, Dr. Garofalo has served on the Board of Acadia Pharmaceuticals Inc. and, since March 2021, as a Board director and member of the Audit Committee at Exicure Inc. Ian Mortimer, who takes on the role of CEO and joins our board of directors, has worked alongside me for the past seven years and is ideally suited to lead Xenon.